PF-AtlasКлинические испытания › NCT06012500

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Xenon-129 · Фаза 1

ID реестра
NCT06012500
Фаза
Фаза 1
Статус
Активно, набор закрыт
Препарат / вмешательство
Xenon-129
Спонсор
Children's Hospital Medical Center, Cincinnati
Начало
2022-04-14
Набор участников
78
Центры
1

Об исследовании

The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using non-invasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs). We base this study on the demonstrated promise of 129Xe as a biomarker for both prognosis and therapy response, overwhelming interest from both industry and academic partners, and impending FDA approval for 129Xe ventilation MRI. This requires disseminating standardized and repeatable methods for 3D 129Xe functional MRI in order to facilitate innovative multi-center observational and interventional trials that can advance our understanding of fibrotic lung disease, while accelerating the development of novel therapies.

Открыть NCT06012500 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT06012500 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.